利记

Our Mission
Inclusive and Open to Diversity,
Innovationoriented to Win Together
and Benefit the Mankind

Haihe Biopharma
Pioneering the Future
of Original
Oncology Drugs

Haihe Stories
Our Scientists

Haihe Mission

Our Mission and Purpose

Research and Development

More R&D Pipelines

Haihe Stories

Our Scientists

About Us

Established in

2011
Headquartered in

Pudong

Shanghai

China
China

Indigenous

Innovative

Biopharma

Company
Specializing in the Discovery,

Development, Production

and Commercialization

Innovative Oncology

Drugs
Academician1

Scientists141

Doctorate
Degree29

Number of
Employees233

Master’s
Degree61

As of FEB.29,2024
Core Products

in R&D Pipeline

10+

R&D Field

Strong, Innovation-driven R&D Capabilities

Have obtained multiple proprietary global intellectual property rights
Multiple global clinical research projects are ongoing simultaneously
Have been recognized by authoritative industry institutions

Cancer Types Covered by the R&D Pipeline

Lung Cancer

Breast Cancer

Gastric Cancer

Gynecological Cancer

Hematologic Malignancies

Rich and Balanced Pipeline

1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications

Company Milestones

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide.

March 2023

Haihe Biopharma’s Gumarontinib has been approved by NMPA
March 2022

NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Gumarontinib
February 2022

The NDA for Haihe Biopharma’s Gumarontinib has been accepted for review by the CDE.
March 2021

Haihe established its Japan office
July 2020

Haihe completed worth
1.2 billion yuan Series B Funding
July 2020

Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.
December 2019

Haihe established its US office
October 2019

Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan
April 2019

Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer
February 2019

Haihe completed Haihe completed $136.6 million Series A Funding
September 2018

Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosesciences, 3D Medicines, and Jiuzhou Pharmaceutical
March 2018

Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

Interviews

I am glad that some research achievements in China in the field of oncology drugs have already been on par with global leaders. Especially in personalized research, China is carrying out projects concurrently with the world, and striving to be a leader in certain aspects.

Academician Jian Ding:
Make Good Drugs that Ordinary People Can Afford

（Xinmin Evening News，2020-11-18）

I often tell myself to work hard and seize every opportunity. I also often inspire my team to develop good drugs that ordinary people can afford, so that new drugs created by Chinese scientists will come onto the global stage as soon as possible.

News Center

Haihe Biopharma Presented results of two clinical studies in 2024 CSCO Annual Meeting

Haihe Biopharma Announces that Paclitaxel Oral Solution (RMX3001) was Approved by NMPA as Second-line Treatment for Gastric Cancer

Haihe Biopharma and Taiho Pharmaceutical Announce the Launch of MET Inhibitor HAIYITAN® Tablets 50mg in Japan

An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan

Haihe Biopharma Presented results of two clinical studies in 2024 ASCO Annual Meeting

Haihe Biopharma are presenting two drug discovery projects in 2024 AACR Annual Meeting

Haihe Biopharma Enters Exclusive License Agreement with Taiho Pharma for Gumarontinib (SCC244), an Agent for Non-Small Cell Lung Cancer

Haihe Biopharma will present two preclinical research in 2024 AACR Annual Meeting

Haihe Biopharma Announces Results from the Phase Ib Study of EZH1/2 Inhibitor HH2853 presented at the 2023 ASH Annual Meeting

Haihe Biopharma Announces CDE Granted Breakthrough Therapy Designation to Gumarontinib for Non-small Cell Lung Cancer with MET Overexpression

Join Us

Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.

Job Opportunities

| Legal statement | Disclaimers | Contact |

Follow Us

©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备69024719号-1

利记